Publication:
Targeting Receptor Kinases in Colorectal Cancer.

Simple item page
dc.contributor.authorGarcía-Aranda, Marilina
dc.contributor.authorRedondo, Maximino
dc.date.accessioned2024-02-10T20:01:03Z
dc.date.available2024-02-10T20:01:03Z
dc.date.issued2019-03-27
dc.description.abstractColorectal cancer is the third most common malignancy in men and the second most common cancer in women. Despite the success of screening programs and the development of adjuvant therapies, the global burden of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. In recent years, a great effort has been made to demonstrate the utility of protein kinase inhibitors for cancer treatment. Considering this heterogeneous disease is defined by mutations that activate different Receptor Tyrosine Kinases (RTKs) and affect downstream components of RTK-activated transduction pathways, in this review we analyze the potential utility of different kinase inhibitors for colorectal cancer treatment.
dc.format.number4es_ES
dc.format.volume11es_ES
dc.identifier.doi10.3390/cancers11040433
dc.identifier.issn2072-6694
dc.identifier.journalCancerses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/13778
dc.identifier.pubmedID30934752es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17837
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCancer
dc.subjectColorectal
dc.subjectKinases
dc.subjectReceptor
dc.subjectTarget
dc.titleTargeting Receptor Kinases in Colorectal Cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
Files
Collections
IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)